[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.119.171. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 24, 2002

Chelation Therapy for Patients With Ischemic Heart Disease—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor

JAMA. 2002;287(16):2077-2078. doi:10.1001/jama.287.16.2073

In Reply: Dr Bell and Dr Strassberg both conclude that adverse clinical events in our study were more frequent in the placebo group. In fact, 7 patients in the placebo group and 10 patients in the EDTA group had a major cardiac event (death, myocardial infarction, or need for revascularization or hospitalization for accelerating symptoms). A single item on the adverse event list, angioplasty, was performed in 4 patients in the placebo group but in none in the EDTA group, but this is not a statistically significant difference and it should not be cited as evidence that EDTA can be used to avoid cardiac procedures. Major adverse cardiac events were not end points in our study because it did not have sufficient statistical power to detect a difference in these low-frequency events.

First Page Preview View Large
First page PDF preview
First page PDF preview
×